BioTie Therapies Corp.: Nepicastat Study In Cocaine Dependence Completes Enrollment Ahead Of Schedule - Top-Line Data Expected Around End 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Biotie: nepicastat study in cocaine dependence completes enrollment ahead of schedule - top-line data expected around end 2014

Biotie Therapies today announced that patient enrollment into the Phase 2 study investigating nepicastat for cocaine dependence has been completed ahead of schedule. The 11-week, 179-patient study is being conducted at 10 US clinics under a Collaborative Research and Development Agreement (CRADA) with the National Institute on Drug Abuse (NIDA) at the US National Institutes of Health. Top-line results from the study are expected around the end of 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news